INTRODUCTION {#S1}
============

Acute myeloid leukemia (AML) is highly heterogenous with treatment outcomes that vary substantially between individual patients.^[@R1],[@R2]^ Among the many established prognostic factors, cytogenetic abnormalities play a central role in the risk categorization and development of risk-stratified treatment algorithms. While classification schemes have evolved with better understanding of the prognostic significance of recurrent cytogenetic abnormalities and slightly differing schemes are used by different groups, they have traditionally separated patients crudely into "favorable", "intermediate", and "adverse" risk groups.^[@R2]--[@R7]^

Still, even among patients with adverse-risk karyotypes, results with conventional chemotherapy and allogeneic hematopoietic cell transplantation (HCT) are not uniform.^[@R8]^ A seminal study identified a monosomal karyotype (MK; karyotype with ≥2 autosomal monosomies or 1 autosomal monosomy with ≥1 structural abnormality) as a new cytogenetic entity with particularly low probability of long-term survival with standard chemotherapy (4-year estimates of \<5%).^[@R8]^ Numerous studies have subsequently confirmed this association.^[@R9]--[@R21]^ While results with allogeneic HCT appear better than with non-HCT post-remission therapies, several studies -- including one from our institution -- have reported poor post-HCT outcomes for adults with MK AML.^[@R10]--[@R12],[@R14],[@R15],[@R18]--[@R22]^

Based on these data, it is now generally accepted that having MK AML is an important adverse prognostic factor for patients undergoing allogeneic HCT. However, to what degree these outcomes are accounted for by the presence of measurable ('minimal') residual disease (MRD) before HCT is unknown. This is particularly important because multivariable models from several transplant and non-transplant studies suggest the presence of MRD is the dominant risk factor for adverse treatment outcome that largely, albeit not completely, accounts for the prognostic significance of adverse-risk cytogenetics.^[@R23]--[@R25]^ To study the relationship between MK, pre-HCT MRD and post-HCT outcomes, we examined a large cohort of adults with AML who underwent allogeneic HCT in first or second complete remission (CR) at our institution between April 2006 and January 2019 and whom we had data from available for multiparameter flow cytometry (MFC)-based MRD testing before HCT.

PATIENTS AND METHODS {#S2}
====================

Study cohort {#S3}
------------

Adults 18 years of age or older with AML (2016 WHO criteria^[@R26]^) were included if 1) they had their first allogeneic HCT with peripheral blood or bone marrow as a stem cell source while in first or second morphologic remission and 2) data were available from routine karyotyping at the time of AML diagnosis. We included all patients from 4/2006 (when a refined ten-color MFC-based MRD assay was introduced and utilized routinely in all HCT patients) until 1/2019. Results from 437 of the 606 patients in the final dataset have been partially reported in previous publications.^[@R23],[@R24],[@R27]--[@R32]^ All patients were treated on Institutional Review Board-approved research protocols or standard treatment protocols and gave consent in accordance with the Declaration of Helsinki. Follow-up was current as of October 30, 2019.

Classification of disease risk at diagnosis and cytogenetic analysis at the time of HCT {#S4}
---------------------------------------------------------------------------------------

We used the refined MRC/NCRI criteria^[@R6]^ to assign cytogenetic risk at diagnosis based on local cytogenetic data. At the time of HCT, marrow and/or blood samples were examined for cytogenetic abnormalities as part of our institutional pre-transplant work-up using standard G-banding techniques and karyotyped according to the International System for Human Cytogenetic Nomenclature.^[@R33]^ We included numerical aberrations and structural abnormalities in our analysis. An abnormality was considered clonal when at least two metaphases had the same aberration in case of a structural abnormality or an extra chromosome. In case of a monosomy, it had to be present in at least three metaphases. In case of a missing number of analyzed metaphases in the records, but fluorescence in situ hybridization (FISH) showing the same abnormalities as the G-banding analysis, this karyotype was also considered to be clonal. We considered independent structural abnormalities and/or numerical aberrations but not marker chromosomes for the designation of complex karyotypes. Among the 606 patients, 248 had a normal karyotype based on ≥20 normal metaphases examined (n=197) or \<20 metaphases examined (n=51); following the approach by Breems and colleagues,^[@R8]^ all of these patients were considered to have cytogenetically normal AML.

MFC detection of MRD {#S5}
--------------------

Ten-color MFC was performed in all patients as a routine clinical test on bone marrow aspirates obtained before conditioning therapy was started as described previously.^[@R23],[@R24],[@R27]--[@R29]^ MRD was identified by visual inspection as a cell population showing deviation (typically seen in more than one antigen) from the normal patterns of antigen expression found on specific cell lineages at specific stages of maturation as compared with either normal or regenerating marrow based on the tested antibody panel.^[@R23],[@R24],[@R27]--[@R29]^ The assay is able to detect MRD in the large majority of cases down to a level of 0.1% and in progressively smaller subsets of patients as the level of MRD decreases below that level. When identified, the abnormal population was quantified as a percentage of the total CD45^+^ white cell events. Any measurable level of MRD was considered positive.^[@R23],[@R24],[@R27]--[@R29]^

Statistical Analysis {#S6}
--------------------

Unadjusted probabilities of relapse-free survival (RFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and probabilities of relapse were summarized using cumulative incidence estimates. NRM was defined as death without prior relapse and was considered a competing risk for relapse. Cox regression and competing risk sub-distribution regression models were used to assess covariate associations with outcomes. Covariates evaluated were: MK (yes *vs*. no), first or second remission at time of HCT (remission 1 *vs*. remission 2), pre-HCT MRD (yes *vs*. no), conditioning regimen (MAC *vs*. RIC), cytogenetic risk group at time of AML diagnosis (intermediate *vs*. adverse), type of AML at diagnosis (secondary *vs*. de novo), presence of complex cytogenetics (yes *vs*. no), karyotype at time of HCT (normalized *vs*. not normalized for patients presenting with abnormal karyotypes), peripheral blood counts at the time of HCT (recovered *vs*. not recovered), age at time of HCT, and white blood cell (WBC) count at time of diagnosis. Categorical patient characteristics were compared using Fisher's exact test and quantitative characteristics were compared with the Wilcoxon rank sum test. Two-sided p-values are reported. Statistical analyses were performed using STATA 16.0 (StataCorp LP, College Station, TX) and R (<http://www.r-project.org>).

RESULTS {#S7}
=======

Characteristics of study cohort {#S8}
-------------------------------

We identified 705 adults with AML undergoing a first allogeneic MAC, RIC, or Mini HCT in first or second morphologic remission between 4/2006 and 1/2019. Excluding patients who did not agree to their data being used for research purposes (n=9), those who did not undergo MRD testing at our institution during the pre-HCT work-up (n=10), those with favorable-risk cytogenetics (n=46; MK is only defined for patients with intermediate- and adverse-risk cytogenetics^[@R8]^), and those with unknown karyotype at the time of AML diagnosis (n=34), our study cohort was comprised of 606 patients. Among these, 68 (11%) had MK AML, including 59 (87%) with complex cytogenetics with ≥3 abnormalities and 56 (82%) with complex cytogenetics with ≥4 abnormalities, compared to 46 (9%) and 23 (4%) of the 538 patients with non-MK AML (both *P*\<0.001). Basic characteristics of the study population and HCT details are summarized in [Table 1](#T1){ref-type="table"}. There were several statistically significant differences between patients with MK AML and those with non-MK AML. Specifically, MK AML patients more often had adverse-risk and complex cytogenetics (both *P*\<0.001), had a lower WBC at diagnosis (*P*=0.0001), and more often had secondary AML (*P*=0.003). Their duration of remission before HCT was shorter (*P*=0.0054) and they more often were transplanted in first remission (*P*=0.004). Importantly, MK AML patients more often were MRD^pos^ than non-MK AML patients (49% vs. 18%; *P*\<0.001) and more likely had persistent cytogenetic abnormalities at the time of HCT (44% *vs*. 13%; *P*\<0.001).

Relationship between pre-HCT MRD status and post-HCT outcome for MK AML and non-MK AML patients in the entire study cohort {#S9}
--------------------------------------------------------------------------------------------------------------------------

By the day of data cut-off, 200 of the 606 patients (41 with MK-AML) relapsed of whom 172 (39 with MK-AML) have died. One hundred and twenty-nine patients (10 with MK-AML) experienced NRM, for a total of 301 deaths (49 among MK-AML patients) following transplantation ([Table 2](#T2){ref-type="table"}). The median follow-up time after HCT in the 305 patients alive at last contact was 63.6 (range 8.4--158.0) months (for MK-AML patients \[n=20\]: 41.5 \[9.9--155.5\] months; for non-MK AML patients \[n=295\]: 65.0 \[8.4--158.0\] months). Consistent with our previous analyses,^[@R23],[@R24],[@R27]--[@R29]^ the 128 patients with MRD before HCT had a significantly higher risk of relapse and shorter RFS as well as shorter OS than the 478 MRD^neg^ patients whereas the risk of NRM was similar ([Table 3](#T3){ref-type="table"}). Similarly in line with a previous report from our institution,^[@R11]^ the 68 patients with MK AML had a significantly higher risk of relapse and shorter RFS and OS but not NRM than the 538 non-MK AML patients ([Table 3](#T3){ref-type="table"}). The relapse risk remained higher, and RFS and OS shorter, for MK AML patients even when stratified by pre-HCT MRD status ([Figure 1](#F1){ref-type="fig"} and [Table 3](#T3){ref-type="table"}). Specifically, among MRD^neg^ patients, estimates for the 3-year cumulative incidence of relapse, 3-year RFS, and 3-year OS were 46% (95% confidence interval: 29--63%), 42% (28--66%), and 48% (43--62%) for MK AML and 20% (16--24%), 60% (55--65%), and 64% (59--68%) for non-MK AML, respectively. Among the MRD^pos^ patients, estimates for relapse incidence, RFS, and OS at 3 years were 72% (55--90%), 9% (4--30%), and 15% (6--36%) for MK AML and 64% (55--74%), 21% (14--31%), and 38% (29--49%) for non-MK AML.

We then developed uni- and multivariable regression models for relapse, RFS, OS, and NRM. In the entire cohort, the unadjusted hazard ratio of MK AML *vs*. non-MK AML for relapse was 2.78 (1.96--3.94, *P*\<0.001; [Table 4](#T4){ref-type="table"}), the unadjusted hazard ratio for failure for RFS was 2.20 (1.63--2.96, *P*\<0.001), and the unadjusted hazard ratio for overall mortality was 2.22 (1.63--3.02, *P*\<0.001). For MRD^pos^ *vs*. MRD^neg^ remission, unadjusted hazard ratios were 4.56 (3.44--6.06; *P*\<0.001) for relapse, 3.06 (2.42--3.86; *P*\<0.001) for RFS, and 2.40 (1.89--3.05; *P*\<0.001) for overall mortality. As summarized in [Table 4](#T4){ref-type="table"}, statistically significant associations with relapse, RFS, and/or OS were also found for several other covariates including WBC at the time of AML diagnosis, and age at time of transplantation, cytogenetic risk, presence of complex (≥4) cytogenetic abnormalities, remission status (first vs second remission), conditioning intensity, and karyotype at the time of HCT but not type of AML (secondary *vs*. de novo). After adjustment for various covariates as summarized in [Table 5](#T5){ref-type="table"}, being MRD^pos^ before transplantation was associated with significantly increased relapse risk (HR=3.88 \[2.83--5.31\], *P*\<0.001), shorter RFS (HR=2.72 \[2.10--3.52\], *P*\<0.001), and shorter OS (hazard ratio \[HR\]=2.03 \[1.55--2.66\], *P*\<0.001) relative to being MRD^neg^ before transplantation. On the other hand, having MK AML was not independently associated with relapse (*P*=0.30), RFS (*P*=0.35), or OS (*P*=0.24) in our multivariable models.

Relationship between pre-HCT MRD status and post-HCT outcome for MK AML and non-MK AML in distinct patient subsets {#S10}
------------------------------------------------------------------------------------------------------------------

We performed subset analyses to examine the relationship between pre-HCT MRD status and outcomes in MK AML and non-MK AML separately in patients transplanted in first remission, those who underwent transplantation after myeloablative conditioning, and those receiving a fully HLA-matched allograft. Among the 485 patients transplanted in first remission, 63 (13%) had MK AML. Basic characteristics of these patients and the 422 non-MK AML patients are summarized in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. Estimates of relapse, RFS, and OS are depicted in [Figure 2A](#F2){ref-type="fig"}--[C](#F2){ref-type="fig"}. As shown in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}, we found very similar hazard ratios for having MK AML vs. not having MK AML as those obtained in the entire study cohort with regard to relapse (HR=2.00 \[1.98--4.24\], *P*\<0.001), RFS (HR=2.27 \[1.65--3.13\], *P*\<0.001), and OS (HR=2.27 \[1.63--3.16\], *P*\<0.001). Similar to what we found in the entire study cohort, having MK AML was no longer independently associated with relapse (*P*=0.58), RFS (*P*=0.53), or OS (*P*=0.47) after multivariable adjustment whereas being MRD^pos^ remained independently associated with higher risk of relapse (HR=4.17 \[2.88--6.04\], *P*\<0.001), shorter RFS (HR=3.16 \[2.34--4.28\], *P*\<0.001), and shorter OS (HR=2.39 \[1.73--3.28\], *P*\<0.001; [Supplementary Table 3](#SD1){ref-type="supplementary-material"}).

Among the 358 patients who underwent myeloablative HCT, 42 (12%) had MK AML. Basic characteristics of these patients and the 316 non-MK AML patients are summarized in [Supplementary Table 4](#SD1){ref-type="supplementary-material"}. Estimates of relapse, RFS, and OS in this patient subset are depicted in [Figure 2D](#F2){ref-type="fig"}--[F](#F2){ref-type="fig"}. As shown in [Supplementary Table 5](#SD1){ref-type="supplementary-material"}, hazard ratios for having MK AML vs. not having MK AML were 2.91 (1.85--4.58) for relapse (*P*\<0.001), 2.13 (1.43--3.17) for RFS (*P*\<0.001), and 2.05 (1.35--3.10) for OS (*P*=0.001). After multivariable adjustment, having MK AML was no longer independently associated with relapse (*P*=0.48), RFS (*P*=0.60), or OS (*P*=0.36) whereas being MRD^pos^ remained independently associated with higher risk of relapse (HR=6.10 \[4.06--9.18\], *P*\<0.001), shorter RFS (HR=4.05 \[2.90--5.67\], *P*\<0.001), and shorter OS (HR=3.08 \[2.17--4.37\], *P*\<0.001; [Supplementary Table 6](#SD1){ref-type="supplementary-material"}).

Finally, among the 509 patients who underwent HCT with HLA-matched allografts (55 \[11%\] of whom had MK AML; [Supplementary Table 7](#SD1){ref-type="supplementary-material"}), estimates of relapse, RFS, and OS are shown in [Figure 2G](#F2){ref-type="fig"}--[I](#F2){ref-type="fig"}. As summarized in [Supplementary Table 8](#SD1){ref-type="supplementary-material"}, hazard ratios for having MK AML vs. not having MK AML were 3.13 (2.11--4.64) for relapse (*P*\<0.001), 2.17 (1.53--3.06) for RFS (*P*\<0.001), and 2.11 (1.48--3.01) for OS (*P*\<0.001). After multivariable adjustment, having MK AML was no longer independently associated with relapse (*P*=0.35), RFS (*P*=0.51), or OS (*P*=0.41) whereas being MRD^pos^ remained independently associated with higher risk of relapse (HR=3.95 \[2.78--5.62\], *P*\<0.001;), shorter RFS (HR=2.79 \[2.08--3.73\], *P*\<0.001), and shorter OS (HR=2.01 \[1.48--2.74\], *P*\<0.001; [Supplementary Table 9](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#S11}
==========

Several studies have indicated that adults with MK AML are essentially non-curable with conventional chemotherapies.^[@R8],[@R9],[@R12],[@R13],[@R17],[@R20]^ Although some of the reported outcomes with allogeneic HCT seemed better than what was observed with other post-remission therapies, the recurrent notion that relapse rates are very high and survival estimates short after transplantation^[@R10]--[@R12],[@R14],[@R15],[@R18]--[@R22]^ may have decreased enthusiasm to expose patients to the risks associated with allografting. The findings from our large retrospective single-institution study confirm that adults with intermediate- or adverse-risk AML and MK have worse post-HCT outcomes than corresponding patients without MK AML, with the 3-year cumulative incidence of relapse approaching 60% in our cohort of MK AML patients (as compared to less than 30% for the non-MK AML patients). Nonetheless, their relapse-free and overall survival estimates range between 25% and 30%. While this is substantially lower than the estimates for non-MK AML patients (around 55--60%), our data suggest a significant subset of MK AML patients will experience longer-term AML-free survival after allogeneic HCT, lending support for the continued use of this treatment strategy for MK AML.

As key finding in our study, post-HCT outcomes are not uniform among adults with MK AML. Rather, our study is the first to identify the MRD status before HCT as a critically important prognostic factor in this subset of AML patients. Perhaps not surprisingly given their relative resistance to conventional chemotherapies, we found a much higher proportion of MK AML patients to have evidence of residual disease during the pre-transplant work-up. Specifically, as assessed by MFC, MK AML patients were almost 3-times as likely to have MRD at that time than those with non-MK AML. Relative to MK AML patients in MRD^neg^ remission, patients with MK AML in MRD^pos^ remission had a significantly higher risk of relapse within 3 years (72% *vs*. 46%) and lower 3-year estimates of RFS (9% *vs*. 46%) and OS (15% *vs*. 43%). In univariate analyses, both having MK AML and presence of MRD were statistically significantly associated with increased relapse risk as well as shorter RFS and OS. Without adjustment, hazard ratios for MK AML *vs*. non-MK AML and MRD^pos^ *vs*. MRD^neg^ remission were relatively similar. After accounting for several covariates (age, WBC at diagnosis, presence of complex karyotype, first *vs*. second remission, karyotype at the time of HCT, peripheral blood counts at the time of HCT, and conditioning intensity), having MRD at the time of HCT remained statistically highly significantly associated with higher relapse risks and shorter survival, similar to what we and others have previously reported.^[@R25],[@R34]^ On the other hand, after multivariable adjustment, having MK AML was no longer statistically significantly associated with higher relapse risks or shorter survival. We obtained qualitatively similar results in our entire study cohort as well as subset analyses, in which we focused on patients transplanted in first morphologic remission, those who received myeloablative conditioning, and those who received fully HLA-matched allografts. Together, these models suggest that the worse outcomes after allogeneic HCT observed in MK AML compared to non-MK AML are largely accounted for by the presence of other adverse prognostic factors, in particular MRD, rather than having MK AML *per se*. From a clinical perspective, these findings suggest that close attention should be paid to the MRD status of MK AML patients considered for allogeneic HCT for informed decision-making and the development of novel treatment strategies aimed to improve post-HCT outcomes for MK AML.

As a particular strength of our study, bone marrow assessment that includes MFC-based MRD testing is routinely performed as part of the pre-HCT work-up since 2006 in a largely unchanged fashion. With this, we were able to include essentially all adults with AML undergoing allogeneic HCT in first or second morphologic remission in our analysis. As a result, ours is the largest single-institution study to date examining post-transplant outcomes of MK AML patients. During that period, patients with AML were routinely assigned to myeloablative conditioning unless significant comorbidities were present, or patients were enrolled onto trials comparing conditioning intensities. Results from pre-HCT MRD testing were available to the treating physicians for all patients comprising our study cohort. However, while the presence of MRD was perceived as a marker for increased risk of post-HCT disease recurrence, it typically played no major role in the selection of the type of preparative regimen.

As one important limitation of our study, the majority of patients was referred to our institution for transplantation after receiving induction and consolidation chemotherapy elsewhere. Therefore, molecular testing, including for mutations in *NPM1*, *FLT3*, *CEBPA*, *ASXL1*, and *RUNX1*, was not routinely performed and data on mutations could thus not be included in our analyses. We also did not have information on mutations in *TP53* routinely available, mutations of particular interest for patients with MK AML given the strong association between MK AML and *TP53* abnormalities.^[@R35]--[@R38]^ Other study limitation to consider include its retrospective nature, the fact that transplant protocol assignments were done in a non-randomized fashion, the relatively short follow-up time for patients transplanted most recently in our cohort, and the relative small number of MK patients, resulting in relatively large confidence intervals for outcome estimates. Moreover, some subset analyses of potential interest, e.g. assessing the relations of MK, pre-HCT MRD, and post-transplant outcomes in people transplanted in second remission or those receiving non-myeloablative conditioning, could not be done because of limited sample sizes in individual patient subgroup. Acknowledging these limitations, the data from our large retrospective analysis indicate that patients with MK AML more often have MRD at the time of HCT than those with non-MK AML. While our study confirms higher relapse rates and shorter survival for MK-AML compared to non-MK AML patients, our multivariable analyses suggest that these adverse outcomes are largely accounted for by the presence of other adverse prognostic factors, in particular MRD.
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![Association between pre-transplant MRD status and post-transplant outcome for 68 adults with MK AML and 538 adults with non-MK AML undergoing allogeneic HCT while in first or second morphologic remission.\
Estimates of **(A)** cumulative risk of relapse (CIR), **(B)** relapse-free survival (RFS), **(C)** overall survival (OS), and **(D)** cumulative risk of non-relapse mortality (NRM) following allogeneic HCT. Outcome estimates are shown individually for MK AML patients in MRD^neg^ remission (n=35) or MRD^pos^ remission (n=33) as well as non-MK AML patients in MRD^neg^ remission (n=443) or MRD^pos^ remission (n=95), respectively.](nihms-1549827-f0001){#F1}

![Post-transplant outcomes for distinct subsets of patients with MK AML and non-MK AML, stratified by pre-transplant MRD status.\
Estimates of **(A)** cumulative risk of relapse (CIR), **(B)** relapse-free survival (RFS), and **(C)** overall survival (OS) for adults with MK AML (n=63) or non-MK AML (n=422) undergoing allogeneic HCT while in first morphologic remission. Estimates of **(D)** CIR, **(E)** RFS, and **(F)** OS for adults with MK AML (n=42) or non-MK AML (n=316) undergoing allogeneic HCT in first or second morphologic remission after myeloablative conditioning. Estimates of **(G)** CIR, **(H)** RFS, and **(I)** OS for adults with MK AML (n=55) or non-MK AML (n=454) undergoing HCT in first or second morphologic remission with HLA-matched allografts.](nihms-1549827-f0002){#F2}

###### 

Demographic and clinical characteristics of entire study cohort, stratified by monosomal and non-monosomal karyotype

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                            Monosomal karyotype\   Non-monosomal karyotype\   All patients\        *P*-value
                                                                                            (n=68)                 (n=538)                    (n=606)              
  ----------------------------------------------------------------------------------------- ---------------------- -------------------------- -------------------- ------------------------------------------
  **Median age at diagnosis (range), years**                                                56 (20--76)            56 (18--77)                56 (18--77)          0.50

  **Median age at HCT (range), years**                                                      56 (20--77)            57 (18--80)                57 (18--80)          0.64

  **Male gender, n (%)**                                                                    41 (60%)               292 (54)                   333 (55)             0.37

  **HCT-CI, n (%)**                                                                                                                                                0.90

   0                                                                                        5 (8)                  43 (9)                     48 (9)               

   1--2                                                                                     19 (31)                167 (34)                   186 (33)             

   ≥3                                                                                       38 (61)                285 (58)                   323 (58)             

   Missing                                                                                  6                      43                         49                   

  **Median WBC at diagnosis (range), x10**^**3**^**/μL**                                    1.9 (0.2--126.0)       8.0 (0.4--347.5)           6.9 (0.2--347.5)     0.0001

  **Cytogenetic risk, n (%)**                                                                                                                                      \<0.001

   Intermediate                                                                             1 (1)                  430 (80)                   431 (71)             

   Adverse                                                                                  67 (99)                108 (20)                   175 (29)             

  **Complex cytogenetics, n (%)**                                                                                                                                  

   ≥3 abnormalities                                                                         59 (87)                46 (9)                     105 (17)             \<0.001

   ≥4 abnormalities                                                                         56 (82)                23 (4)                     79 (13)              \<0.001

  **Secondary AML**                                                                                                                                                0.003

   No                                                                                       37 (54)                390 (72)                   427 (70)             

   Yes                                                                                      31 (46)                148 (28)                   179 (30)             

  **Median CR duration before HCT (range), days**                                           85 (16--356)           99 (11--574)               98 (11--574)         0.0054

  **Remission status, n (%)**                                                                                                                                      0.004

   First remission                                                                          63 (93)                422 (78)                   485 (80)             

   Second remission                                                                         5 (7)                  116 (22)                   121 (20)             

  **Pre-HCT MRD status, n (%)**                                                                                                                                    \<0.001

   MRD^neg^                                                                                 35 (51)                443 (82)                   478 (79)             

   MRD^pos^                                                                                 33 (49)                95 (18)                    128 (21)             

    Median % abnormal blasts (range)                                                        0.2 (0.007--10.0)      0.8 (0.007--19.4)          0.49 (0.007--19.4)   

  **Recovered peripheral blood counts before HCT[\*](#TFN1){ref-type="table-fn"}, n (%)**   51 (75)                382 (71)                   433 (71)             0.57

  **Recovered ANC before HCT[\*](#TFN1){ref-type="table-fn"}, n (%)**                       62 (91)                499 (93)                   561 (93)             0.62

  **Recovered platelet count before HCT[\*](#TFN1){ref-type="table-fn"}, n (%)**            51 (75)                388 (72)                   439 (72)             0.67

  **Routine karyotyping before HCT, n (%)**                                                                                                                        \<0.001

   Normalized karyotype                                                                     37 (54)                190 (35)                   227 (37)             

   Abnormal karyotype                                                                       30 (44)                71 (13)                    101 (17)             

   Missing/non-informative data                                                             1 (1)                  277 (51)                   278 (46)             

  **Unrelated donor, n (%)**                                                                47 (69)                360 (67)                   407 (67)             0.79

  **HLA matching, n (%)**                                                                                                                                          0.37

   Fully matched                                                                            55 (81)                454 (84)                   509 (84)             

   1-allele mismatch                                                                        9 (13)                 67 (12)                    76 (13)              

   2-allele mismatch                                                                        0 (0)                  4 (1)                      4 (1)                

   Haplo-identical                                                                          4 (6)                  13 (2)                     17 (3)               

  **Conditioning regimen**                                                                                                                                         0.64[\*\*\*](#TFN3){ref-type="table-fn"}

   MAC                                                                                      42 (62)                316 (59)                   358 (59)             

    Containing high-dose TBI (≥12 Gy)                                                       6 (9)                  42 (8)                     48 (8)               

    Not containing high-dose TBI                                                            36 (53)                274 (51)                   310 (51)             

   RIC                                                                                      13 (19)                92 (17)                    105 (17)             

   Mini[\*\*](#TFN2){ref-type="table-fn"}                                                   13 (19)                130 (24)                   143 (24)             

  **Stem cell source, n (%)**                                                                                                                                      0.14

   PBSC                                                                                     57 (84)                484 (90)                   541 (89)             

   BM                                                                                       11 (16)                54 (10)                    65 (11)              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ANC ≥1,000/μL and platelets ≥100,000/μL.

Conditioning with fludarabine and TBI 2--3 Gy.

Comparison MAC *vs*. RIC *vs*. Mini.

[Abbreviations]{.ul}: ANC, absolute neutrophil count; BM, bone marrow; FLU, fludarabine; HCT, hematopoietic cell transplantation; HCT-CI, HCT-specific Comorbidity Index; MAC, myeloablative conditioning; MRD, measurable residual disease; PBSC, peripheral blood stem cells; RIC, reduced-intensity conditioning; TBI, total body irradiation; WBC, total white blood cell count.

###### 

Number of events in entire study population and stratified by monosomal and non-monosomal karyotype conditioning therapy (n=606)

                     Relapses   Deaths with prior relapse   Deaths without prior relapse   Total number of deaths
  ------------------ ---------- --------------------------- ------------------------------ ------------------------
  **All patients**   200        172                         129                            301
  **MK AML**         41         39                          10                             49
  **Non-MK AML**     159        133                         119                            252

###### 

Outcome probabilities (with 95% confidence interval) of entire study cohort stratified by monosomal karyotype and pre-HCT MRD status

                                CI of relapse at 3 years   RFS at 3 years   OS at 3 years   CI of NRM at 3 years
  ----------------------------- -------------------------- ---------------- --------------- ----------------------
  **All patients**                                                                          
  All (n=606)                   31% (27--35%)              50% (46--54%)    56% (52--60%)   19% (16--22%)
  MRD^neg^ (n=478)              22% (18--26%)              58% (54--63%)    62% (58--67%)   20% (16--24%)
  MRD^pos^ (n=128)              66% (58--74%)              18% (13--27%)    32% (25--41%)   16% (9--22%)
                                                                                            
  **Monosomal karyotype**                                                                   
  All (n=68)                    59% (46--71%)              26% (17--40%)    29% (19--43%)   16% (6--25%)
  MRD^neg^ (n=35)               46% (29--63%)              46% (32--66%)    43% (29--65%)   13% (1--25%)
  MRD^pos^ (n=33)               72% (55--90%)              9% (4--30%)      15% (6--36%)    19% (5--33%)
                                                                                            
  **Non-monosomal karyotype**                                                               
  All (n=538)                   28% (24--32%)              53% (49--57%)    59% (54--63%)   19% (16--23%)
  MRD^neg^ (n=443)              20% (16--24%)              60% (55--65%)    64% (59--68%)   20% (17--24%)
  MRD^pos^ (n=95)               64% (55--74%)              21% (14--31%)    38% (29--49%)   15% (8--22%)

[Abbreviations]{.ul}: CI, cumulative incidence; HCT, hematopoietic cell transplantation; MRD, measurable residual disease; NRM, non-relapse mortality; OS, overall survival; RFS, relapse-free survival.

###### 

Univariate regression models for entire study cohort (n=606)

                                                               Relapse                         Failure for RFS                 Overall mortality
  ------------------------------------------------------------ ------------------------------- ------------------------------- -------------------------------
  **Monosomal karyotype**                                                                                                      
  ** **No (n=538)                                              1 (Reference)                   1 (Reference)                   1 (Reference)
  ** **Yes (n=68)                                              2.78 (1.96--3.94), *P*\<0.001   2.20 (1.63--2.96), *P*\<0.001   2.22 (1.63--3.02), *P*\<0.001
  **Pre-HCT MRD Status**                                                                                                       
  ** **MRD^neg^ (n=478)                                        1 (Reference)                   1 (Reference)                   1 (Reference)
  ** **MRD^pos^ (n=128)                                        4.56 (3.44--6.06), *P*\<0.001   3.06 (2.42--3.86), *P*\<0.001   2.40 (1.89--3.05), *P*\<0.001
  **Remission status**                                                                                                         
  ** **First remission (n=485)                                 1 (Reference)                   1 (Reference)                   1 (Reference)
  ** **Second remission (n=121)                                1.63 (1.19--2.23), *P*=0.003    1.49 (1.16--1.92), *P*=0.002    1.47 (1.13--1.91), *P*=0.004
  **Conditioning Regimen**                                                                                                     
  ** **MAC (n=358)                                             1 (Reference)                   1 (Reference)                   1 (Reference)
  ** **RIC/Mini (n=248)                                        1.29 (0.97--1.70), *P*=0.08     1.57 (1.26--1.95), *P*\<0.001   1.64 (1.30--2.06), *P*\<0.001
  **Age (per 10 years)**                                       0.99 (0.88--1.10), *P*=0.80     1.10 (1.01--1.19), *P*=0.032    1.14 (1.05--1.25), *P*=0.003
  **WBC at diagnosis (per 10,000/μL)** (n=596)                 1.01 (0.91--1.11), *P*=0.91     1.02 (1.00--1.04), *P*=0.019    1.02 (1.00--1.05), *P*=0.018
  **Cytogenetic risk**                                                                                                         
  ** **Intermediate (n=431)                                    1 (Reference)                   1 (Reference)                   1 (Reference)
  ** **Adverse (n=175)                                         1.87 (1.41--2.48), *P*\<0.001   1.26 (1.00--1.60), *P*=0.048    1.14 (0.89--1.46), *P*=0.29
  **Complex karyotype[\*](#TFN6){ref-type="table-fn"}**                                                                        
  ** **No (n=527)                                              1 (Reference)                   1 (Reference)                   1 (Reference)
  ** **Yes (n=79)                                              2.55 (1.83--3.56), *P*\<0.001   1.85 (1.38--2.47), *P*\<0.001   1.91 (1.41--2.57), *P*\<0.001
  **Type of AML**                                                                                                              
  ** **De novo (n=427)                                         1 (Reference)                   1 (Reference)                   1 (Reference)
  ** **Secondary (n=179)                                       0.97 (0.72--1.32), *P*=0.86     1.07 (0.84--1.35), *P*=0.58     1.14 (0.89--1.45), *P*=0.30
  **Pre-HCT karyotype**                                                                                                        
  ** **Normalized (n=227)                                      1 (Reference)                   1 (Reference)                   1 (Reference)
  ** **Not normalized (n=101)                                  1.95 (1.36--2.77), *P*=0.001    1.81 (1.35--2.43), *P*\<0.001   1.74 (1.28--2.38), *P*\<0.001
  **Pre-HCT blood counts[\*\*](#TFN7){ref-type="table-fn"}**                                                                   
  ** **Recovered (n=433)                                       1 (Reference)                   1 (Reference)                   1 (Reference)
  ** **Not recovered (n=173)                                   1.01 (0.74--1.38), *P*=0.95     1.35 (1.07--1.71), *P*=0.011    1.53 (1.20--1.94), *P*=0.001

≥4 cytogenetic abnormalities.

Recovered: ANC ≥1,000/μL and platelets ≥100,000/μL; not recovered: ANC \<1,000/μL and/or platelets \<100,000/μL.

###### 

Multivariable regression models of entire study cohort

                                                               Relapse                         Failure for RFS                 Overall mortality
  ------------------------------------------------------------ ------------------------------- ------------------------------- -------------------------------
  **Monosomal karyotype**                                                                                                      
  ** **Yes (*vs*. no)                                          1.36 (0.76--2.42), *P*=0.30     1.27 (0.77--2.08), *P*=0.35     1.38 (0.81--2.36), *P*=0.24
  **Pre-HCT MRD Status**                                                                                                       
  ** **MRD^pos^ (*vs*. MRD^neg^)                               3.88 (2.83--5.31), *P*\<0.001   2.72 (2.10--3.52), *P*\<0.001   2.03 (1.55--2.66), *P*\<0.001
  **Remission status**                                                                                                         
  ** **Second (*vs*. first) remission                          1.96 (1.37--2.80), *P*\<0.001   1.63 (1.23--2.15), *P*=0.001    1.46 (1.09--1.94), *P*=0.010
  **Conditioning Regimen**                                                                                                     
  ** **RIC/Mini (*vs*. MAC)                                    1.64 (1.16--2.30), *P*=0.001    1.81 (1.39--2.35), *P*\<0.001   1.67 (1.27--2.21), *P*\<0.001
  **Age (per 10 years)**                                       0.90 (0.79--1.05), *P*=0.10     0.97 (0.88--1.07), *P*=0.51     1.01 (0.91--1.12), *P*=0.89
  **WBC at diagnosis (per 10,000/μL)**                         1.03 (1.00--1.05), *P*=0.038    1.04 (1.02--1.06), *P*\<0.001   1.04 (1.01--1.06), *P*=0.001
  **Complex karyotype[\*](#TFN8){ref-type="table-fn"}**                                                                        
  ** **Yes (*vs*. no)                                          1.42 (0.85--2.40), *P*=0.18     1.35 (0.85--2.14), *P*=0.21     1.54 (0.93--2.55), *P*=0.093
  **Pre-HCT karyotype**                                                                                                        
  ** **Not normalized (*vs*. normalized)                       1.33 (0.90--1.87), *P*=0.15     1.36 (0.98--1.88), *P*=0.06     1.17 (0.82--1.65), *P*=0.38
  **Pre-HCT blood counts[\*\*](#TFN9){ref-type="table-fn"}**                                                                   
  ** **Not recovered (*vs*. recovered)                         0.71 (0.49--1.02), *P*=0.06     1.00 (0.78--1.29), *P*=0.99     1.25 (0.97--1.62), *P*=0.08

≥4 cytogenetic abnormalities.

Recovered: ANC ≥1,000/μL and platelets ≥100,000/μL; not recovered: ANC \<1,000/μL and/or platelets \<100,000/μL.
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